Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34796
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPitre, Tyler-
dc.contributor.authorLupas, Daniel-
dc.contributor.authorEbeido, Ibrahim-
dc.contributor.authorColak, Alexander-
dc.contributor.authorModi, Mihir-
dc.contributor.authorKachkovski, George V-
dc.contributor.authorMontesi, Sydney B-
dc.contributor.authorKhor, Yet H-
dc.contributor.authorKawano-Dourado, Leticia-
dc.contributor.authorJenkins, Gisli-
dc.contributor.authorFisher, Jolene H-
dc.contributor.authorShapera, Shane-
dc.contributor.authorRochwerg, Bram-
dc.contributor.authorCouban, Rachel-
dc.contributor.authorZeraatkar, Dena-
dc.date2023-
dc.date.accessioned2024-01-04T04:03:30Z-
dc.date.available2024-01-04T04:03:30Z-
dc.date.issued2024-02-
dc.identifier.citationRespiratory Medicine 2024-02; 222en_US
dc.identifier.issn1532-3064-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34796-
dc.description.abstractAcute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) increases mortality risk, but which factors increase mortality is unknown. We aimed to perform a prognostic review of factors associated with mortality in patients with IPF. and methods: We searched MEDLINE, EMBASE, and CINAHL for studies that reported on the association between any prognostic factor and AE-IPF. We assessed risk of bias using the QUIPS tool. We conduced pairwise meta-analyses using REML heterogeneity estimator, and GRADE approach to assess the certainty of the evidence. We included 35 studies in our analysis. We found that long-term supplemental oxygen at baseline (aHR 2.52 [95 % CI 1.68 to 3.80]; moderate certainty) and a diagnosis of IPF compared to non-IPF ILD (aHR 2.19 [95 % CI 1.22 to 3.92]; moderate certainty) is associated with a higher risk of death in patients with AE-IPF. A diffuse pattern on high resolution computed tomography (HRCT) compared to a non-diffuse pattern (aHR 2.61 [95 % CI 1.32 to 2.90]; moderate certainty) is associated with a higher risk of death in patients with AE-IPF. We found that using corticosteroids prior to hospital admission (aHR 2.19 [95 % CI 1.26 to 3.82]; moderate certainty) and those with increased neutrophils (by % increase) in bronchoalveolar lavage (BAL) during the exacerbation is associated with a higher risk of death (aHR 1.02 [1.01 to 1.04]; moderate certainty). Our results have implications for healthcare providers in making treatment decisions and prognosticating the clinical trajectory of patients, for researchers to design future interventions to improve patient trajectory, and for guideline developers in making decisions about resource allocation.en_US
dc.language.isoeng-
dc.subjectAcute exacerbationsen_US
dc.subjectIPFen_US
dc.subjectMeta-analysisen_US
dc.subjectPrognostic factorsen_US
dc.titlePrognostic factors associated with mortality in acute exacerbations of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleRespiratory Medicineen_US
dc.identifier.affiliationDivision of Respirology, Department of Medicine, University of Toronto, Toronto, ON, Canada.en_US
dc.identifier.affiliationSchulich School of Medicine & Dentistry, Western University, London, ON, Canada.en_US
dc.identifier.affiliationFaculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.en_US
dc.identifier.affiliationFaculty of Medicine, University of British Columbia, BC, Canada.en_US
dc.identifier.affiliationSchulich School of Medicine & Dentistry, Western University, London, ON, Canada.en_US
dc.identifier.affiliationFaculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.en_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.affiliationHcor Research Institute, Hospital do Coracao, Sao Paulo, Brazil; Pulmonary Division, University of Sao Paulo, Sao Paulo, Brazil; MAGIC Evidence Ecosystem, Oslo, Norway.en_US
dc.identifier.affiliationMargaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, UK.en_US
dc.identifier.affiliationDivision of Respirology, Department of Medicine, University of Toronto, Toronto, ON, Canada.en_US
dc.identifier.affiliationDivision of Respirology, Department of Medicine, University of Toronto, Toronto, ON, Canada.en_US
dc.identifier.affiliationDepartment of Medicine, McMaster University, Hamilton, ON, Canada; Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada.en_US
dc.identifier.affiliationDepartment of Anesthesiology, McMaster University, Hamilton, ON, Canada.en_US
dc.identifier.affiliationDepartment of Medicine, McMaster University, Hamilton, ON, Canada; Department of Anesthesiology, McMaster University, Hamilton, ON, Canada.en_US
dc.identifier.doi10.1016/j.rmed.2023.107515en_US
dc.type.contentTexten_US
dc.identifier.pubmedid38154738-
dc.description.startpage107515-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.